BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)
Supplemental material
Ann Rheum Dis
Supplementary Table 2 . Persistent COVID-19 symptoms and other patient-reported outcomes in rheumatic disease patients following COVID-19 infection among those who did not receive either monoclonal antibodies or nirmatrelvir/ritonavir
Non- breakthrough COVID-19
Breakthrough COVID-19 infection (N=64)
All rheumatic disease patients (N=214)
p-value
infection (N=150)
Days to acute symptom resolution or date of survey if symptoms ongoing, median [IQR] CDC Definition of PASC (COVID-19 symptoms lasting at least 28 days post-COVID- 19 infection) WHO Definition of PASC (COVID-19 symptoms lasting at least 90 days post-COVID- 19 infection)*
30 (10, 120)
25 (8, 57)
30 (12, 216)
0.01
108 (50)
27 (42)
81 (54)
0.14
60 (35)
3 (9)
57 (51)
0.01
Pain (SF-MPQ) N
193
60
133
Median score [IQR]
5 (2, 10)
3 (1, 7)
6 (3, 10)
0.02
Pain rating index ordinal categories, n (%)
0.05
No pain
31 (14)
8 (13)
23 (15)
Mild pain
64 (30)
27 (42)
37 (25)
Discomforting, distressing, horrible, or excruciating pain
102 (48)
25 (39)
77 (51)
Fatigue (FSI) N
199
60
139
Median score [IQR]
51 (25, 80)
36 (14, 68)
55 (28, 84)
0.02
Functional status (mHAQ) N
205
61
144
Median score [IQR]
0.1 (0.0, 0.4)
0.1 (0.0, 0.4)
0.2 (0.0, 0.5)
0.42
Functional status categorical score, n (%)
0.08
Normal (<0.3)
128 (60)
44 (69)
84 (56)
Mild, moderate, or severe (0.3 to >1.8) Health status (SF-12) PCS-12 score, median [IQR]
77 (36)
17 (27)
60 (40)
42.3 (32.8, 51.0)
44.6 (36.4, 53.9) 49.1 (39.7, 56.0)
41.1 (32.1, 49.9)
0.09
MCS-12 score, median [IQR] 49.9 (39.1, 56.3)
50.7 (37.8, 57.1)
0.98
2022;0:1–9. doi: 10.1136/ard-2022-223439 Ann Rheum Dis , et al. Patel NJ
Powered by FlippingBook